5 stories found
Senior executives and directors at numerous publicly traded companies have recently filed disclosures for substantial stock sales. The transactions span multiple industries and reflect routine insider trading activity reported to financial regulators.
Alector's stock has seen a rise after BTIG upgraded the company's rating to Buy, citing a strategic shift.
Alector revealed it will attend multiple upcoming healthcare industry conferences to showcase its immunology research and development programs. Management intends to discuss pipeline advancements with potential partners and investors.
Alector reported a GAAP EPS of -$0.34 and revenue of $6.2 million for its recent financial quarter.
Alector's stock dropped by 13% following the termination of its neuroscience partnership with GSK.